Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than a buck. -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (288)	12/28/1999 7:04:00 AM
From: The Dodgy Ticker	Read Replies (1) \| Respond to of 743

Richard, I enjoy your thread and wish you happy holidays. Congratulations on Small Wonders. You asked folks to share a favorite company which is still under a buck. Well, mine is Antex (ANTX). Although Rick isn't impressed with it, it's been growing well and has some strong collaborations. However, it appears to be a long-term hold rather than one which will catch favor in the near term. Cheers and best wishes, Bob

To: RWReeves who wrote (288)	12/28/1999 5:41:00 PM
From: RWReeves	Read Replies (1) \| Respond to of 743

Report Card time "Small Wonders" The portfolio that started out as "Biotech for Less Than a Buck (BTFLTAB)is now 90 days old (inception 9/28/99): siliconinvestor.com Performance: 90 days: + 83.5 % 1 day -1.2 % I will probably leave this unchanged and edit a revised version of the portfolio with a different name (a Millenium edition of SW?) for the position changes I've discussed recently. I cut back several positions to free up investment capital for more new issues and cut back some poor performers for "window dressing". All in all many issues did better than expected. ARIA obviously we had great expectations for, added a big double up position and it did OK. I expected to see 5 bucks by now, however. Laggard. LGNDW I had a $5 target for it and it hit it earlier in the month. I expected LSCP to be bought out, which has not happened (yet). NERX and IMMU are riding the cancer therapeutics move. As I mentioned, IMMU is a 10 bagger on the original position in 90 days; something I did not forsee (obviously) when I sold them out and bought them back at around 3.5. Good example of re-alignment of assets for maximum value. No real genomics plays although I have a few in the works and an anti-sense or two (ISIP, come to me!) Oddly enough, I think the buy it and forget it strategy worked well, with the volatility in these issues it seems daytrading would probably have done poorer. Will look to add some options next year as well. Best Wishes for your New Year celebrations and Y2K investments. RWR

To: RWReeves who wrote (288)	12/30/1999 2:24:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 743

Cortex has a nice little presentation you can page through--slides from the annual meeting a couple weeks ago. cortexpharm.com They always show the long lists of potential indications...well, I wouldn't buy it for that slide...but they seem to have a good patent portfolio. Any thoughts on that? And what is the point of the Amgen Alzheimer's slide? Well, I guess you would have to have been there. Seems like a relatively safe speculation, heheh, I cant belive I just said that. Did you make your IRA target? Gosh, what to do if I get to my goal...well, I'll just worry about that when if it happens in a couple years.